Results 11 to 20 of about 82,244 (295)
Addiction Science & Clinical Practice, 2023 Background We use a novel, longitudinal approach to describe average time spent in opioid use disorder (OUD) cascade of care stages for people with HIV (PWH) and with OUD, incorporating four definitions of treatment retention.
Jarratt D. Pytell +7 more
doaj +1 more source
Buprenorphine Waiver Attitudes Among Primary Care Providers
Journal of Primary Care & Community Health, 2022 Background: Despite efforts to improve access to Medications for Opioid Use Disorder (MOUD), such as buprenorphine, the number of opioid overdoses in the United States continues to rise.
Benjamin Lai +2 more
doaj +1 more source
Single high-dose buprenorphine for opioid craving during withdrawal. [PDF]
, 2018 BackgroundOpioid use disorder is one of the most prevalent addiction problems worldwide. Buprenorphine is used as a medication to treat this disorder, but in countries where buprenorphine is unavailable in combination with naloxone, diversion can be a ...
Ahmadi, Jamshid +3 more
core +2 more sources
Western Journal of Emergency Medicine, 2023 Objective: Buprenorphine is an evidence-based treatment for opioid use disorder that is underused in the emergency department (ED). In this study we evaluated changes in emergency physician knowledge, confidence, and self-efficacy regarding buprenorphine
Michelle L. Myles +5 more
doaj +1 more source
The SUMMIT trial: a field comparison of buprenorphine versus methadone maintenance treatment. [PDF]
, 2010 This prospective patient-preference study examined the effectiveness in practice of methadone versus buprenorphine maintenance treatment and the beliefs of subjects regarding these drugs. A total of 361 opiate-dependent individuals (89% of those eligible,
Holland, R +5 more
core +1 more source
Selective review and commentary on emerging pharmacotherapies for opioid addiction. [PDF]
, 2011 Pharmacotherapies for opioid addiction under active development in the US include lofexidine (primarily for managing withdrawal symptoms) and Probuphine®, a distinctive mode of delivering buprenorphine for six months, thus relieving patients, clinicians,
Ling, Walter +5 more
core +2 more sources
Adapting low-dose buprenorphine induction to meet patient needs: A pilot study
Drug and Alcohol Dependence Reports, 2022 Introduction: Low-dose buprenorphine induction (LDBI) has been proposed to initiate buprenorphine in patients who are taking full opioid agonists in order to limit the risk of precipitated withdrawal.
Zoe A. Karavolis, Payel J. Roy
doaj +1 more source
Substance Abuse Treatment, Prevention, and Policy, 2022 Background and aims In the United States, access to buprenorphine remains low and disparities regarding who receives treatment have emerged. Federal laws have regulated buprenorphine delivery, ultimately limiting its implementation more broadly.
Barrot H. Lambdin +2 more
doaj +1 more source
Indian Journal of Anaesthesia, 2010 Neuraxial opioids provide excellent analgesia intraoperatively and postoperatively while allowing early ambulation of the patient by sparing sympathetic and motor nerves. A prospective, randomised double blind study was conducted involving 90 patients of
Shaloo Ipe +5 more
doaj +1 more source
Comparison of Buprenorphine and Buprenorphine/naloxone in Detoxification of Opioid-dependent Men [PDF]
Addiction and Health, 2018 Background: Buprenorphine sublingual tablets are now available in Iran for opioid detoxification in clinics. Aim of the present study was to compare the efficiency of buprenorphine with buprenorphine/naloxone in short-term detoxification in a group of ...
Hassan Ziaaddini +4 more
doaj +1 more source